Evidence map›Paper›PMID 37508525›Full record

ArticleCells2023

N-Acetylaspartate Drives Oligodendroglial Differentiation via Histone Deacetylase Activation.

Alessandra Dominicis, Alice Del Giovane, Matteo Torreggiani, Antonella Damiana Recchia, Fabio Ciccarone, Maria Rosa Ciriolo, Antonella Ragnini-Wilson

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. The Emerging Role of N-Acetylaspartate in Cancer.International journal of molecular sciences · 2026
    Review
  4. Cholinergic Phenotypes of Acetyl-CoA with ATP-Citrate Lyase Link.International journal of molecular sciences · 2026
    Review
  5. Aspartate in the Brain: A Review.Neurochemical research · 2025
    Review
  6. Article
  7. Mitochondrial dysfunction in chronic neuroinflammatory diseases (Review).International journal of molecular medicine · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alessandra DominicisDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Alice Del GiovaneDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Matteo TorreggianiDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Antonella Damiana RecchiaDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Fabio CiccaroneDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-2425-2240
Maria Rosa CirioloDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-7863-9029
Antonella Ragnini-WilsonDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-7963-7554
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An unmet clinical goal in demyelinating pathologies is to restore the myelin sheath prior to neural degeneration. N-acetylaspartate (NAA) is an acetylated derivative form of aspartate, abundant in the healthy brain but severely reduced during traumatic brain injury and in patients with neurodegenerative pathologies. How extracellular NAA variations impact the remyelination process and, thereby, the ability of oligodendrocytes to remyelinate axons remains unexplored. Here, we evaluated the remyelination properties of the oligodendroglial (OL) mouse cell line Oli-neuM under different concentrations of NAA using a combination of biochemical, qPCR, immunofluorescence assays, and in vitro engagement tests, at NAA doses compatible with those observed in healthy brains and during brain injury. We observed that oligodendroglia cells respond to decreasing levels of NAA by stimulating differentiation and promoting gene expression of myelin proteins in a temporally regulated manner. Low doses of NAA potently stimulate Oli-neuM to engage with synthetic axons. Furthermore, we show a concentration-dependent expression of specific histone deacetylases essential for MBP gene expression under NAA or Clobetasol treatment. These data are consistent with the idea that oligodendrocytes respond to lowering the NAA concentration by activating the remyelination process via deacetylase activation.

Indexed as

Aspartic AcidHistone DeacetylasesAnimalsCell DifferentiationMiceMyelin SheathAspartic AcidHistone DeacetylasesN-acetylaspartateepigeneticshistone deacetylases (HDACs)multiple sclerosis (MS)N-acetylaspartate (NAA)neurodegenerationOli-neuMremyelination

Identifiers

PMID37508525
PMCPMC10378218
OpenAlexW4384557742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.